XOLAIR (also known as Omalizumab)

Mechanism:

Xolair is an antibody that binds to human immunoglobulin E (IgE) and prevents the activation of cells that would otherwise mediate allergic reactions.

Indications:

Adults and adolescents (age >= 12) with moderate to severe asthma with positive skin test for perennial allergens and whose symptoms are not adequately controlled with inhaled corticosteroids.

Cautions:

Xolair should not be used for acute asthma exacerbations.

Administration:

Xolair is typically administered as a subcutaneous injection by a healthcare administrator.  Patient should be monitored afterwards for possible allergic reaction.